Olfactory Outcomes of Dupilumab Treatment for Nasal Polyposis

Recruiting now · Phase 4

Conditions studied: Chronic Rhinosinusitis With Nasal Polyps, Olfactory Disorder

In brief

The study aims to investigate the olfactory TDI score (Threshold, Discrimination, Identification) using the Sniffin' sticks test for patients with chronic rhinosinusitis with nasal polyps (CRSwNP) on dupilumab. Twenty-seven adult patients will be followed up during the treatment with dupilumab on three visits to the Otolaryngology Clinic (Baseline, 3 months and 6 months). The primary endpoint will be the TDI score. Nasal polyp score, Quality of Olfactory Disorders - negative symptoms (QOD-NS symptom scores), SNOT-22 will be secondary endpoints.

Key facts

Study ID

NCT04869436

Run by

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

People needed

27

Starts

2021-07-19

Expected to finish

2025-12-01

Last updated by the study team

2024-12-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients older than 18 years old
• Chronic rhinosinusitis with Nasal Polyps
• Olfactory loss
• Clinical indication for treatment with Dupilumab

You may not qualify if…

• Patients with olfactory loss from other causes such as:
• Sinonasal malignancies
• Trauma
• Idiopathic olfactory loss
• Use of cocaine
• COVID-19 related olfactory loss
• Pregnancy

Where it is running

• St. Joseph's Health Care — London, Ontario, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.